Great Minds Think Unlike

Founded in 2021, Neumirna is pioneering a new frontier in the treatment of neurological diseases.

Based in Copenhagen, our team brings together world-class expertise in neuroscience and RNA biology

Neumirna was founded by an experienced team with the curiosity to question conventional thinking and the determination to build a better path forward. Some of the most important breakthroughs in science have come from unexpected combinations of minds and different disciplines working together to challenge assumptions and reframe problems.

We bring that spirit into our work, believing that real progress comes when diverse minds come together to cross boundaries and open entirely new ways forward.

Our goal is to lessen the burden for patients with epilepsy, Parkinson's disease, and other neurological conditions, especially those who have run out of options.

That is why we call it a new frontier in medicine

Scientific Founders

World-leading experts in drug development of RNA Therapeutics and Neuroscience

Heading 2

Donec id elit non mi porta gravida at eget metus. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Curabitur blandit tempus porttitor. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Dr. Henrik Klitgaard
Scientific Co-Founder, Board Member

Henrik is a pioneering neuroscientist with a distinguished career in epilepsy research and drug development. As Vice President for Neuroscience at UCB, he led the team that discovered the novel Synaptic Vesicle 2A (SV2A) mechanism, leading to the development of two groundbreaking antiepileptic drugs: Levetiracetam (Keppra), the first blockbuster epilepsy treatment, and Brivaracetam (Briviact).

In addition to his contributions to drug discovery, Henrik has been engaged in the epilepsy research community. He is a former member of the Scientific Committee at Citizens United for Research in Epilepsy and currently serves on the External Consultant Board of the NIH's Epilepsy Therapy Screening Project.

In recognition of his dedication to advancing epilepsy treatments, Henrik was honored with the Accelerator Award from the US Epilepsy Foundation, celebrating his long-standing commitment to improving the lives of those affected by epilepsy.

Prof. Sakari Kauppinen‍
Scientific Co-Founder

Sakari Kauppinen serves as Professor at the Department of Clinical Medicine, Aalborg University and Director of the Center for RNA Medicine. His research focuses on the discovery of RNA-targeted therapeutics for unmet medical needs, and exploring the roles of non-coding RNAs in health and disease.

Before joining Aalborg University, he was Senior Director of miRNA Research & Drug Discovery at Santaris Pharma (acquired by Roche in 2014) where he supervised the discovery of Miravirsen – the world’s first miRNA-targeted drug.

As a key member of the clinical development team, he played a pivotal role in advancing Miravirsen to Phase 2 clinical trials, demonstrating on-target efficacy against HCV infection with a strong safety profile.

Sakari is also Co-Founder of Resalis Therapeutics, a clinical-stage company for the treatment of metabolic disorders. In 2019, he received $9.2 M from the Novo Nordisk Foundation to establish a NASH Research Consortium.